Navigation Links
QuikByte Software, Inc. Announces Changes to Board of Directors and Executive Ranks
Date:7/7/2008

MIAMI, July 7 /PRNewswire-FirstCall/ -- QuikByte Software, Inc. (OTC Bulletin Board: QBYT) today announced the following changes to its Board of Directors and executive leadership:

Mr. Glenn L. Halpryn was appointed the Chairman, President and Chief Executive Officer of the Company, Mr. Alan Jay Weisberg was appointed the Chief Financial and Accounting Officer and a director of the Company, Mr. Noah M. Silver was appointed the Vice President, Secretary, Treasurer and a director of the Company, and Dr. Curtis Lockshin and Mr. Ronald Stein were each appointed directors of the Company.

The prior directors and officers of the Company resigned before the effectiveness of the appointments.

The appointments and resignations were made in connection with the sale by certain of the Company's shareholders of approximately 94% of the issued and outstanding shares of the Company's common stock to various investors, including Messrs. Halpryn, Weisberg, Silver and Stein. Following the sale, the Company's largest shareholder is Mr. Steven Jerry Glauser, a Denver-based investor. Additional information regarding these transactions is available in QuikByte's reports filed with the Securities and Exchange Commission, which may be accessed at sec.gov/edgar.shtml.

QuikByte Software, Inc. is a "shell company" with no operating assets or business. The Company's plan of business is to identify and evaluate a merger or other business combination with an operating company. No assurance can be given as to when or if the Company will be successful in doing so.

Forward Looking Statements:

This release contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA). Actual results may differ from those projected due to a number of risks and uncertainties, including, but not limited to the possibility that some or all of the pending matters and transactions considered by QuikByte Soft
'/>"/>

SOURCE QuikByte Software, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. March of Dimes Announces Nursing Scholarship Recipients
2. Zix Corporation Announces Webcast Showcasing Email Encryption Competitive Replacement
3. Digestive Care, Inc. Announces the Filing of the First Module of NDA Submission for PANCRECARB(R) (pancrelipase)
4. Mindray Announces 20-F Filing
5. Mergent, Inc. Announces Changes to the HealthShares(TM) Ophthalmology Index
6. Senetek Announces Termination of Invicorp(R) License Agreement With Ardana Bioscience Limited
7. Mylan Announces Tentative FDA Approval for Generic Version of Antibiotic Zyvox(R) Tablets
8. Hooper Holmes Announces Sale of Claims Evaluation Division
9. Transition Therapeutics Announces Executive Management Appointments
10. Chindex International, Inc. Announces Receipt of Key Regulatory ApprovalsChina SFDA Certificates Received Include Intuitive Surgical daVinci S
11. Ambulatory Services of America, Inc. Announces the Acquisition of Dialysis Operations in St. Louis, Missouri
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Ameritox(R) Appoints Jay B. Zimmerman as Chief Operating Officer 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 4Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 5Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 6Bayer Consumer Care Voluntarily Recalls One Lot of Combination Package of Alka-Seltzer Plus(R) Day & Night Cold Formula Liquid Gels 2New Swine Flu Strain Found in Brazil 3A Report 49266 1New Swine Flu Strain Found in Brazil 3A Report 49266 2New Swine Flu Strain Found in Brazil 3A Report 49266 3New Swine Flu Strain Found in Brazil 3A Report 49266 4New Swine Flu Strain Found in Brazil 3A Report 49266 5New Swine Flu Strain Found in Brazil 3A Report 49266 6New Swine Flu Strain Found in Brazil 3A Report 49266 7New Swine Flu Strain Found in Brazil 3A Report 49266 8New Swine Flu Strain Found in Brazil 3A Report 49266 9New Swine Flu Strain Found in Brazil 3A Report 49266 10New Swine Flu Strain Found in Brazil 3A Report 49266 11New Swine Flu Strain Found in Brazil 3A Report 49266 12Fathers 26apos 3B Hearing Affects Family Function and Fiscal Health 49263 1Fathers 26apos 3B Hearing Affects Family Function and Fiscal Health 49263 2Fathers 26apos 3B Hearing Affects Family Function and Fiscal Health 49263 3Fathers 26apos 3B Hearing Affects Family Function and Fiscal Health 49263 4MedNet Solutions Unveils New Naming and Functionality for its Flagship EDC eClinical Offering 12678 1MedNet Solutions Unveils New Naming and Functionality for its Flagship EDC eClinical Offering 12678 2